Wirkstoffe & Arzneimittelsicherheit

Gegenanzeigen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5–6

HOS-109427 · Präparat HOS-093201

5  • Sirolimus • Naloxegol • Tolvaptan • Finerenone • Eplerenone • Voclosporin • Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration phase.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): eplerenone (HOS-089050) finerenone (HOS-109430) tolvaptan (HOS-109429) venetoclax (HOS-086143) naloxegol (HOS-109428) sirolimus (HOS-085172) voclosporin (HOS-109432)

Gegenanzeigen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 36

HOS-109524 · Präparat HOS-093201

• Terfenadine • Astemizole • Cisapride • Pimozide • Lurasidone • Quinidine • Ivabradine • Ergot alkaloids (e.g., ergotamine, dihydroergotamine) • Sirolimus • Naloxegol • Tolvaptan • Finerenone • Eplerenone • Voclosporin • Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration phase.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)

Gegenanzeigen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 69

HOS-109587 · Präparat HOS-093201

• Terfenadine • Astemizole • Cisapride • Pimozide • Lurasidone • Quinidine • Ivabradine • Ergot alkaloids (e.g., ergotamine, dihydroergotamine) • Sirolimus • Naloxegol • Tolvaptan • Finerenone • Eplerenone • Voclosporin

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17

HOS-109484 · Präparat HOS-093201

16 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48–49

HOS-109554 · Präparat HOS-093201

48 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80–81

HOS-109619 · Präparat HOS-093201

80 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Gegenanzeigen · Voriconazole Hikma (previously Voriconazole Hospira)

Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 5–6

HOS-130910 · Präparat HOS-096981

• Terfenadine • Astemizole • Cisapride • Pimozide • Lurasidone • Quinidine 5 • Ivabradine • Ergot alkaloids (e.g., ergotamine, dihydroergotamine) • Sirolimus • Naloxegol • Tolvaptan • Finerenone • Eplerenone • Voclosporin • Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration phase.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)

Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)

Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 17–18

HOS-130968 · Präparat HOS-096981

17 Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax ↑ 20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-∞ ↑ 100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax ↑ 114% needed. Diclofenac AUC0-∞ ↑ 78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax ↑ 1.7-fold other long-acting opiates Oxycodone AUC0-∞ ↑ 3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax ↑ 31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUCτ ↑ 47% reactions and toxicity related to S-methadone Cmax ↑ 65% methadone, including QTc S-methadone AUCτ ↑ 103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-∞ ↑ 6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 µg/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-∞ ↑ 1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax ↑ 36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUCτ ↑ 61% related to oral contraceptives, in inhibitor] Norethisterone Cmax ↑ 15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUCτ ↑ 53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax ↑ 14% Voriconazole AUCτ ↑ 46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Gegenanzeigen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 7

HOS-145288 · Präparat HOS-099328

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Concomitant treatment with strong inhibitors of CYP3A4 (see section 4.5), e.g., - itraconazole - ketoconazole - ritonavir - nelfinavir - cobicistat - clarithromycin - telithromycin - nefazodone - Addison's disease

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) cobicistat (HOS-088111) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521)

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145289 · Präparat HOS-099328

Interaction studies have only been performed in adults.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145290 · Präparat HOS-099328

Finerenone is cleared almost exclusively via cytochrome P450 (CYP)-mediated oxidative metabolism (mainly CYP3A4 [90%] with a small contribution of CYP2C8 [10%]).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145291 · Präparat HOS-099328

Concomitant use contraindicated

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145292 · Präparat HOS-099328

Strong CYP3A4 inhibitors Concomitant use of Kerendia with itraconazole, clarithromycin and other strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin or nefazodone) is contraindicated (see section 4.3), since a marked increase in finerenone exposure is expected.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) cobicistat (HOS-088111) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521)

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145293 · Präparat HOS-099328

Concomitant use not recommended

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145294 · Präparat HOS-099328

Strong and moderate CYP3A4 inducers Kerendia should not be used concomitantly with rifampicin and other strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, St John’s Wort) or with efavirenz and other moderate CYP3A4 inducers. These CYP3A4 inducers are expected to markedly decrease finerenone plasma concentration and result in reduced therapeutic effect (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) efavirenz (HOS-087947) phenytoin (HOS-084531)

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145295 · Präparat HOS-099328

Certain medicinal products that increase serum potassium Kerendia should not be used concomitantly with potassium-sparing diuretics (e.g., amiloride, triamterene) and other MRAs (e.g., eplerenone, esaxerenone, spironolactone, canrenone). It is anticipated that these medicinal products increase the risk for hyperkalaemia (see section 4.4)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) potassium (HOS-086929) spironolactone (HOS-112481) canrenone (HOS-145300)

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-145301 · Präparat HOS-099328

Grapefruit Grapefruit or grapefruit juice should not be consumed during finerenone treatment, as it is expected to increase the plasma concentrations of finerenone through inhibition of CYP3A4 (see sections 4.2 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): grapefruit juice (HOS-088787)

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-145302 · Präparat HOS-099328

9 Concomitant use with precautions

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-145303 · Präparat HOS-099328

Moderate CYP3A4 inhibitors In a clinical study, concomitant use of erythromycin (500 mg three times a day) led to a 3.5-fold increase in finerenone AUC and 1.9-fold increase in its Cₘₐₓ. In another clinical study, verapamil (240 mg controlled-release tablet once daily) led to a 2.7- and 2.2-fold increase in finerenone AUC and Cₘₐₓ, respectively. Serum potassium may increase, and therefore, monitoring of serum potassium is recommended, especially during initiation or changes to dosing of finerenone or the CYP3A4 inhibitor (see sections 4.2 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) potassium (HOS-086929) verapamil (HOS-090602)

Wechselwirkungen · Kerendia

Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-145304 · Präparat HOS-099328

Weak CYP3A4 inhibitors The physiologically based pharmacokinetic (PBPK) simulations suggest that fluvoxamine (100 mg twice daily), increases finerenone AUC (1.6-fold) and Cₘₐₓ (1.4-fold). Serum potassium may increase, and therefore, monitoring of serum potassium is recommended, especially during initiation or changes to dosing of finerenone or the CYP3A4 inhibitor (see sections 4.2 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): potassium (HOS-086929) fluvoxamine (HOS-085908)